- Abbreviation of monoclonal antibody.
- (pharmacology) monoclonal antibody
USAN guidelines for non-proprietary names of monoclonal antibodies are as follows:
- an arbitrary prefix to create a unique name (officially monosyllabic)
- a suffix for the disease state
- a suffix for the animal source
- -mab to identify it as a monoclonal antibody (MAb)
The source suffixes are as follows:
- -a- for rat-derived,
- -e- for hamster,
- -i- for primate,
- -o- for mouse,
- -u- for human,
- -xi- for chimeric,
- -zu- for humanized,
- -xizu- for humanize and chimeric,
- -axo- for rat-mouse hybrid.
The disease target suffixes are:
- -vir- viral,
- -bac- bacterial,
- -lim- immune system, immunomodulator,
- -les- infectious lesions,
- -cir- cardiovascular
- -col- colon tumor,
- -mel- melanoma,
- -mar- mammary tumor,
- -got- testicular (gonad) tumor,
- -gov- ovarian (gonad) tumor,
- -pro- prostate tumor,
- -tum- other tumors, or combinations of the above;
- -ner- nervous system,
- -kin- interleukin,
- -mul- muscoskeletal,
- -os- bone,
- -toxa- toxin,
- -fung- fungus
Other attested target affixes are -anibi- and -neur-. The target affix takes the primary stress.
For instance, capromab is a murine MAb that targets prostate cancer; imiciromab pentatate is used to target myocardial infarctions; satumomab pendetide is used for both colorectal and ovarian cancers.
For humanized (-zu-) and chimeric (-xi-) MAbs (-xizu-), the final consonant of the target suffix is dropped, and for all others the o of -pro- and the a of -toxa- is dropped: natalizumab, a humanized monoclonal antibody used in the treatment of multiple sclerosis (an immunological disease).
- MAb, monoclonal antibody